Compare NPK & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | ANNX |
|---|---|---|
| Founded | 1905 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.1M | 812.7M |
| IPO Year | 1994 | 2020 |
| Metric | NPK | ANNX |
|---|---|---|
| Price | $131.53 | $5.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 76.6K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16,320.74 |
| P/E Ratio | $130.72 | ★ N/A |
| Revenue Growth | ★ 29.70 | N/A |
| 52 Week Low | $84.41 | $1.85 |
| 52 Week High | $149.86 | $7.18 |
| Indicator | NPK | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 44.52 |
| Support Level | $125.99 | $5.28 |
| Resistance Level | $147.83 | $5.61 |
| Average True Range (ATR) | 6.54 | 0.30 |
| MACD | -0.91 | -0.03 |
| Stochastic Oscillator | 28.61 | 40.34 |
National Presto Industries Inc has an eclectic product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments namely Defense, Housewares/Small Appliance, and Safety. The defense segment which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases; performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances; the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.